Literature DB >> 26028302

The mitochondrial-targeted antioxidant, MitoQ, increases liver mitochondrial cardiolipin content in obesogenic diet-fed rats.

Gilles Fouret1, Evanthia Tolika2, Jérôme Lecomte3, Béatrice Bonafos1, Manar Aoun2, Michael P Murphy4, Carla Ferreri2, Chryssostomos Chatgilialoglu5, Eric Dubreucq6, Charles Coudray1, Christine Feillet-Coudray7.   

Abstract

Cardiolipin (CL), a unique mitochondrial phospholipid, plays a key role in several processes of mitochondrial bioenergetics as well as in mitochondrial membrane stability and dynamics. The present study was designed to determine the effect of MitoQ, a mitochondrial-targeted antioxidant, on the content of liver mitochondrial membrane phospholipids, in particular CL, and its fatty acid composition in obesogenic diet-fed rats. To do this, twenty-four 6week old male Sprague Dawley rats were randomized into three groups of 8 animals and fed for 8weeks with either a control diet, a high fat diet (HF), or a HF diet with MitoQ (HF+MitoQ). Phospholipid classes and fatty acid composition were assayed by chromatographic methods in liver and liver mitochondria. Mitochondrial bioenergetic function was also evaluated. While MitoQ had no or slight effects on total liver fatty acid composition and phospholipid classes and their fatty acid composition, it had major effects on liver mitochondrial phospholipids and mitochondrial function. Indeed, MitoQ both increased CL synthase gene expression and CL content of liver mitochondria and increased 18:2n-6 (linoleic acid) content of mitochondrial phospholipids by comparison to the HF diet. Moreover, mitochondrial CL content was positively correlated to mitochondrial membrane fluidity, membrane potential and respiration, as well as to ATP synthase activity, while it was negatively correlated to mitochondrial ROS production. These findings suggest that MitoQ may decrease pathogenic alterations to CL content and profiles, thereby preserving mitochondrial function and attenuating the development of some of the features of metabolic syndrome in obesogenic diet-fed rats.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiolipin; Fatty acids; Hepatic steatosis; High fat diet; Mitochondria; Phospholipids

Year:  2015        PMID: 26028302     DOI: 10.1016/j.bbabio.2015.05.019

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  19 in total

1.  Effect of mitoquinone (Mito-Q) on neuropathic endpoints in an obese and type 2 diabetic rat model.

Authors:  Brian Fink; Lawrence Coppey; Eric Davidson; Hanna Shevalye; Alexander Obrosov; Pratik Rajesh Chheda; Robert Kerns; William Sivitz; Mark Yorek
Journal:  Free Radic Res       Date:  2020-04-24

2.  Mitoquinol mesylate (MITOQ) attenuates diethyl nitrosamine-induced hepatocellular carcinoma through modulation of mitochondrial antioxidant defense systems.

Authors:  Rahmat Adetutu Adisa; Lateef Adegboyega Sulaimon; Ebele Geraldine Okeke; Olubukola Christianah Ariyo; Fatimah B Abdulkareem
Journal:  Toxicol Res       Date:  2021-11-08

3.  Skeletal muscle overexpression of short isoform Sirt3 altered mitochondrial cardiolipin content and fatty acid composition.

Authors:  Béatrice Chabi; Gilles Fouret; Jérome Lecomte; Fabienne Cortade; Laurence Pessemesse; Narjès Baati; Charles Coudray; Ligen Lin; Qiang Tong; Chantal Wrutniak-Cabello; François Casas; Christine Feillet-Coudray
Journal:  J Bioenerg Biomembr       Date:  2018-03-27       Impact factor: 2.945

4.  Skeletal muscle expression of p43, a truncated thyroid hormone receptor α, affects lipid composition and metabolism.

Authors:  François Casas; Gilles Fouret; Jérome Lecomte; Fabienne Cortade; Laurence Pessemesse; Emilie Blanchet; Chantal Wrutniak-Cabello; Charles Coudray; Christine Feillet-Coudray
Journal:  J Bioenerg Biomembr       Date:  2018-01-13       Impact factor: 2.945

Review 5.  Cardiovasomobility: an integrative understanding of how disuse impacts cardiovascular and skeletal muscle health.

Authors:  Joel D Trinity; Micah J Drummond; Caitlin C Fermoyle; Alec I McKenzie; Mark A Supiano; Russell S Richardson
Journal:  J Appl Physiol (1985)       Date:  2022-02-03

6.  Cardiac-specific succinate dehydrogenase deficiency in Barth syndrome.

Authors:  Jan Dudek; I-Fen Cheng; Arpita Chowdhury; Katharina Wozny; Martina Balleininger; Robert Reinhold; Silke Grunau; Sylvie Callegari; Karl Toischer; Ronald Ja Wanders; Gerd Hasenfuß; Britta Brügger; Kaomei Guan; Peter Rehling
Journal:  EMBO Mol Med       Date:  2016-02-01       Impact factor: 12.137

Review 7.  Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

Authors:  Agostino Di Ciaula; Salvatore Passarella; Harshitha Shanmugam; Marica Noviello; Leonilde Bonfrate; David Q-H Wang; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

Review 8.  Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Ignazio Grattagliano; Agostino Di Ciaula; Jacek Baj; Emilio Molina-Molina; Harshitha Shanmugam; Gabriella Garruti; David Q-H Wang; Piero Portincasa
Journal:  Methods Mol Biol       Date:  2021

9.  LPCAT1 controls phosphate homeostasis in a zinc-dependent manner.

Authors:  Mushtak Kisko; Nadia Bouain; Alaeddine Safi; Anna Medici; Robert C Akkers; David Secco; Gilles Fouret; Gabriel Krouk; Mark Gm Aarts; Wolfgang Busch; Hatem Rouached
Journal:  Elife       Date:  2018-02-17       Impact factor: 8.140

10.  Mitochondria-targeted ubiquinone (MitoQ) enhances acetaldehyde clearance by reversing alcohol-induced posttranslational modification of aldehyde dehydrogenase 2: A molecular mechanism of protection against alcoholic liver disease.

Authors:  Liuyi Hao; Qian Sun; Wei Zhong; Wenliang Zhang; Xinguo Sun; Zhanxiang Zhou
Journal:  Redox Biol       Date:  2017-11-11       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.